Gossamer Bio, Inc. (GOSS) NASDAQ

0.39

+0.0125(+3.31%)

Updated at April 22 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Faheem Hasnain	Co-Founder, Chief Executive Officer, President & Chairman	961,995	1958
Christian Waage	Executive Vice President of Technical Operations & Administration	583,156	1967
Richard Aranda	Chief Medical Officer	677,492	1960
Bryan Giraudo	Chief Operating Officer & Chief Financial Officer	739,622	1975
Robert F. Roscigno	Senior Vice President of Clinical Development of Pulmonary Vascular Disease	0	1966
Jeff Boerneke	General Counsel & Secretary	0	N/A
Matt Cravets	Senior Vice President of Biometrics	0	N/A
Caryn L. Peterson	Executive Vice President of Regulatory Affairs	0	1959
Deanna Weber	Executive Vice President of Human Resources	0	N/A
Jeanine Anthony	Senior Vice President of Marketing	0	N/A

Name

Title

Pay

Year Born

Faheem Hasnain

Co-Founder, Chief Executive Officer, President & Chairman

961,995

1958

Christian Waage

Executive Vice President of Technical Operations & Administration

583,156

1967

Richard Aranda

Chief Medical Officer

677,492

1960

Bryan Giraudo

Chief Operating Officer & Chief Financial Officer

739,622

1975

Robert F. Roscigno

Senior Vice President of Clinical Development of Pulmonary Vascular Disease

1966

Jeff Boerneke

General Counsel & Secretary

N/A

Matt Cravets

Senior Vice President of Biometrics

N/A

Caryn L. Peterson

Executive Vice President of Regulatory Affairs

1959

Deanna Weber

Executive Vice President of Human Resources

N/A

Jeanine Anthony

Senior Vice President of Marketing

N/A

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.